Veraxa Biotech officer files Form 3

Veraxa Biotech Holding AG officer Heinz Schwer has filed a Form 3 as Chief Business Officer of VRXA.

Rhea-AI Filing Summary

Veraxa Biotech Holding AG officer Heinz Schwer has filed a Form 3 as Chief Business Officer of VRXA. This is an initial statement of beneficial ownership and shows no reported transactions, with no shares bought, sold, acquired, or disposed of in this filing.

Key Terms

Form 3, Chief Business Officer, reporting person

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3):"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

Chief Business Officer financial

""officer_title": "Chief Business Officer""

A chief business officer (CBO) is the executive responsible for a company's commercial strategy, partnerships, licensing, and business development—essentially the leader who turns technology or products into paying customers and deals. Investors care because the CBO's choices about partnerships, pricing, market entry and revenue models directly influence how fast a company grows and how much future cash flow or value it can deliver; think of the CBO as the company's head coach for winning business and income.

reporting person regulatory

""reportingPersons": [ { "name": "Schwer Heinz""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Veraxa Biotech (VRXA) Form 3 filing by Heinz Schwer indicate?

The Form 3 filing shows that Heinz Schwer, Chief Business Officer of Veraxa Biotech, has reported his initial beneficial ownership status. The insider data for this filing lists no stock transactions and no shares bought, sold, acquired, or disposed of.

Did Heinz Schwer buy or sell Veraxa Biotech (VRXA) shares in this Form 3?

No, the insider data show zero shares bought, sold, acquired, or disposed of in this Form 3. All transaction-related counts, including buys, sells, exercises, gifts, and tax withholdings, are listed as zero in the transaction summary table.

What is Heinz Schwer’s role at Veraxa Biotech (VRXA) in this Form 3?

Heinz Schwer is identified as an officer of Veraxa Biotech with the title Chief Business Officer. The Form 3 confirms his status as a company officer and reporting person, even though it does not report any specific share transactions or holdings here.

Does the Veraxa Biotech (VRXA) Form 3 show any derivative securities for Heinz Schwer?

No, the derivative summary in this Form 3 is empty, indicating no listed options, warrants, or other derivative positions. The transaction summary also shows zero derivative transactions and zero exercise shares associated with Heinz Schwer in this filing.

Is Heinz Schwer reported as a 10% owner in Veraxa Biotech (VRXA) on this Form 3?

No, the insider filing explicitly marks Heinz Schwer as not being a ten percent owner. He is reported only as an officer, serving as Chief Business Officer, with no indication in this document that he holds ten percent or more of Veraxa Biotech shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 07:48 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Schwer Heinz

(Last) (First) (Middle)

TALACKER 35

(Street)

ZURICH 8001

(City) (State) (Zip)

SWITZERLAND

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/09/2026

3. Issuer Name and Ticker or Trading Symbol
Veraxa Biotech Holding AG [ VRXA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Heinz Schwer	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)